Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Brisbane, California
- Most recent report
- 10-Q, filed Oct 13, 2026
- Incorporated
- Delaware
- Filings on record
- 552 filings
- On EDGAR
- CIK 1549595
- Fiscal year ends
- November
- Filer status
- Large accelerated filer
Financials 8 of 25
News 8 of 79
Prospectuses and Registrations 8 of 26
- 424B5 Prospectus supplement for an offering Mar 6, 2026
- S-8 Registration statement for an employee plan Jan 28, 2026
- 424B5 Prospectus supplement for an offering Oct 22, 2025
- FWP Free writing prospectus Oct 22, 2025
- S-8 Registration statement for an employee plan Jan 28, 2025
- 424B5 Prospectus supplement for an offering Oct 31, 2024
- S-8 Registration statement for an employee plan Oct 31, 2024
- 424B5 Prospectus supplement for an offering Jul 11, 2024
Proxies 8 of 12
- DEFA14A Extra proxy material Mar 27, 2026
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2026
- DEFA14A Extra proxy material Mar 28, 2025
- DEF 14A Proxy statement for a shareholder vote Mar 28, 2025
- DEFA14A Extra proxy material Mar 27, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 27, 2024
- DEFA14A Extra proxy material Mar 24, 2023
- DEF 14A Proxy statement for a shareholder vote Mar 24, 2023
Ownership 8 of 379
- 4 Insider reported a trade Oct 15, 2026
- 144 Notice of a proposed sale of restricted stock Oct 14, 2026
- 4 Insider reported a trade Oct 14, 2026
- 4 Insider reported a trade Oct 2, 2026
- 144 Notice of a proposed sale of restricted stock Oct 2, 2026
- SCHEDULE 13G Large holder reported a passive stake Sep 23, 2026
- 4 Insider reported a trade Sep 2, 2026
- 144 Notice of a proposed sale of restricted stock Sep 2, 2026
Other 8 of 31
- ARS Annual report sent to shareholders Mar 27, 2026
- ARS Annual report sent to shareholders Mar 28, 2025
- UPLOAD Comment letter from SEC staff Mar 19, 2025
- CORRESP Reply to SEC staff Mar 13, 2025
- UPLOAD Comment letter from SEC staff Feb 28, 2025
- ARS Annual report sent to shareholders Mar 27, 2024
- EFFECT Notice that a registration became effective Apr 6, 2023
- ARS Annual report sent to shareholders Mar 24, 2023
Everything here comes from Nurix Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.